内皮抑制素与巴马司他合用提高抗血管新生和抗肿瘤功效(英文)  

Enhanced antiangiogenic and antitumoral efficacy by combining endostatin with batimastat

作　　者：欣坚[1] 马小超[1] 邓辉[2] 张婷[1] 屠曾宏[1] 

机构地区：[1]中国科学院上海生命科学院 [2]复旦大学附属华山医院皮肤病研究室,上海200040

出　　处：《中国药理学与毒理学杂志》2003年第5期384-388,共5页Chinese Journal of Pharmacology and Toxicology

摘　　要：目的　研究内皮抑制素与巴马司他合用的抗血管新生和抗肿瘤效果。方法　血管样管腔形成实验用来测定体外血管新生程度。通过测定血红蛋白含量检测体内血管新生程度。小鼠接种Lewis肺癌细胞 ,治疗 1 2d后测量肿瘤重量。结果　内皮抑制素在体外抑制了管腔形成数 (抑制率 33.5 % ) ,在体内减少了血红蛋白含量 (抑制率 38.8% ) ;然而在这两个实验中 ,内皮抑制素与巴马司他合用与单用内皮抑制素相比均显著提高了抑制率 (P <0 .0 5)。接受内皮抑制素的小鼠肿瘤重量减少了 46 .3% ;而接受共同治疗的小鼠肿瘤重量减少了 65 .7%。结论内皮抑制素与巴马司他合用提高了抗血管新生和抗肿瘤功效。AIM To show a combination of endostatin wi th batimastat has more potent antiangiogenic and antitumor effect. METHODS Capillary-like tube formation assay was used to determine angiogenesis in vitro. Hemoglobin content was detected to assess angiogenesis in vivo . Mice were implanted with Lewis lung carcinoma cells, and tu mor weight was measured after 12 d treatment. RESULTS Endostatin treatm ent alone reduced capillary-like tube numbers in vitro(inhibitory rate 33.5%) and hemoglobin content in vivo(inhibitory rate 38 .8%) ; while in the both assays, the combined treatment of endostatin with batimastat all resulted i n a significantly enhanced inhibitory efficacy compared with endostatin treatmen t alone (P&lt;0.05). Tumor weight was reduced by 46.3% in mice treated with endostatin alone; and by 65.7% in mice treated with the combined therapy. CONCLUSION The addition of batimastat to endostatin enhanced antiang iogenic and antitumoral efficacy.

关 键 词：内皮抑制素 巴马司他 血管生成 癌 Lewis肺 药物合用 抗血管新生 抗肿瘤 

分 类 号：R96[医药卫生—药理学]